| Original language | English (US) |
|---|---|
| Pages (from-to) | 1115-1118 |
| Number of pages | 4 |
| Journal | Annals of Oncology |
| Volume | 31 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 2020 |
ASJC Scopus subject areas
- Hematology
- Oncology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Annals of Oncology, Vol. 31, No. 9, 09.2020, p. 1115-1118.
Research output: Contribution to journal › Editorial › peer-review
}
TY - JOUR
T1 - The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10
T2 - a decision centered on empowering patients and their physicians
AU - Subbiah, V.
AU - Solit, D. B.
AU - Chan, T. A.
AU - Kurzrock, R.
N1 - Funding Information: This work was supported by the MD Anderson Cancer Center Support Grant [grant number P30 CA016672 ]. Funding Information: This work was supported by the MD Anderson Cancer Center Support Grant [grant number P30 CA016672]. VS: Research funding/grant support for clinical trials: Roche/Genentech, Novartis, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm, Pharmamar, D3, Pfizer, Multivir, Amgen, Abbvie, Alfasigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint medicines, Loxo Oncology, Medimmune, Altum, Dragonfly Therapeutics, Takeda, and National Comprehensive Cancer Network, NCI-CTEP and UT MD Anderson Cancer Center, Turning Point Therapeutics, Boston Pharmaceuticals; Travel: Novartis, Pharmamar, ASCO, ESMO, Helsinn, Incyte; Consultancy/Advisory board: Helsinn, LOXO Oncology/Eli Lilly, R-Pharma US, INCYTE, QED Pharma, Medimmune, Novartis. Other: Medscape. DBS has consulted for/received honoraria from Loxo Oncology, Lilly Oncology, Pfizer, Vivideon Therapeutics, QED Therapeutics and Illumina. TAC is a co-founder of Gritstone Oncology and holds stock; receives research funding from Bristol-Myers Squibb (BMS), Pfizer, Illumina, Eisai, AstraZeneca, NysnoBio. He is a paid consultant of BMS, Illumina, AstraZeneca, An2H and holds patents for the use of TMB for prediction of clinical benefit from immune checkpoint inhibitors and receives royalties. RK receives research funding from Genentech, Merck Serono, Pfizer, Boehringer Ingelheim, TopAlliance, Takeda, Incyte, Debiopharm, Medimmune, Sequenom, Foundation Medicine, Konica Minolta, Grifols, Omniseq and Guardant, as well as consultant and/or speaker fees and/or advisory board for X-Biotech, Loxo, Neomed, Pfizer, Actuate Therapeutics and Roche, has an equity interest in IDbyDNA and CureMatch Inc, is a cofounder of CureMatch and serves on the Board of CureMatch and CureMetrix.
PY - 2020/9
Y1 - 2020/9
UR - http://www.scopus.com/inward/record.url?scp=85089498915&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089498915&partnerID=8YFLogxK
U2 - 10.1016/j.annonc.2020.07.002
DO - 10.1016/j.annonc.2020.07.002
M3 - Editorial
C2 - 32771306
AN - SCOPUS:85089498915
SN - 0923-7534
VL - 31
SP - 1115
EP - 1118
JO - Annals of Oncology
JF - Annals of Oncology
IS - 9
ER -